Bristol-Myers Squibb

Yahoo Finance • 3 hours ago

Catalyst Watch: Jobs report, new Apple products, and a spotlight on software

[New York Stock Exchange] Selcuk Oner/iStock Editorial via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock pric... Full story

Yahoo Finance • yesterday

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival ("PFS") and overall survival ("OS") in an interim analysis of a Phase 3 trial (NCT06382142) conducted in China BL-B01D1-307 is the third Phase... Full story

Yahoo Finance • 2 days ago

RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts.RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth On February 25, RBC C... Full story

Yahoo Finance • 2 days ago

Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie

Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development. Pharma stocks trade at about a 25% discount to their 10 year averages despite impr... Full story

Yahoo Finance • 2 days ago

NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE... Full story

Yahoo Finance • 4 days ago

FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best value stocks to buy now. On February 17, Bristol Myers Squibb announced that the FDA accepted its NDA for iberdomide, which is an investigational treatment for patients with relaps... Full story

Yahoo Finance • 4 days ago

Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Investor interest in Bristol-Myers Squibb (BMY) has picked up after a cluster of clinical and re... Full story

Yahoo Finance • 4 days ago

FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. FDA accepts Bristol Myers Squibb’s New Drug Application for iberdo... Full story

Yahoo Finance • 4 days ago

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J., February 23, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company will take par... Full story

Yahoo Finance • 4 days ago

Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in.Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential On February 20, Barclays began coverage... Full story

Yahoo Finance • 6 days ago

Down 25%, Should You Buy the Dip on Bristol Myers Squibb?

Pharmaceutical companies spend a ton of money on developing new drugs. Most fail, but those that win regulatory approval and reach the market can generate billions of dollars in sales, all while patents bar competitors from copying them. P... Full story

Yahoo Finance • 7 days ago

Dr. Reddy’s biosimilar for Bristol’s Orencia undergoes FDA review

[US Food and Drug Administration (FDA)] Dr. Reddy’s Laboratories (RDY [https://seekingalpha.com/symbol/RDY]) announced on Friday that the U.S. Food and Drug Administration has accepted for review its marketing application for a biosimilar... Full story

Yahoo Finance • 7 days ago

Barclays launches U.S. biopharma coverage with four preferred picks

Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myer... Full story

Yahoo Finance • 7 days ago

Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More

Company Logo Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic production while reducing costs, fueling market growth and adoption Stem Cell and Regenerative Ther... Full story

Yahoo Finance • 8 days ago

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full... Full story

Yahoo Finance • 8 days ago

3 Stocks to Buy and Hold for 2026 and Beyond

Healthcare is a multi-trillion-dollar industry in the United States alone. With 2024 spending exceeding $5.3 trillion, the sector is nearly one-fifth of the U.S. economy. That alone justifies holding several healthcare stocks in your long-... Full story

Yahoo Finance • 8 days ago

Where is Janux Therapeutics (JANX) Headed According to Analysts?

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best immunotherapy stocks to buy according to hedge funds. JonesTrading maintained a Buy rating on Janux Therapeutics, Inc. (NASDAQ:JANX) on January 23, setting a price target of $50.00.... Full story

Yahoo Finance • 8 days ago

What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best immunotherapy stocks to buy according to hedge funds. Bristol-Myers Squibb Company (NYSE:BMY) announced on February 12 plans to become an inaugural partner to Life Science Cares in... Full story

Yahoo Finance • 8 days ago

Iberdomide Review And AI Alliance Add New Angles To BMY Outlook

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. FDA accepts Bristol Myers Squibb's New Drug Application for iberdomide for relapsed or refractor... Full story

Yahoo Finance • 8 days ago

J&J to build $1bn US CGT manufacturing site in Pennsylvania

Johnson & Johnson (J&J) has chosen Pennsylvania as home to its new $1bn cell therapy manufacturing facility, as the Trump administration looks to onshore drug production to the US amid growing global competition. Once operational, the Mon... Full story